Chardan Affirms ARIAD (ARIA) at 'Buy'; Narrower Label Impacts Iclusig Usage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
ARIAD Pharma (ARIA) Posts Q2 Loss of 30c/Share
August 6, 2014 7:37 AM EDTARIAD Pharma (NASDAQ: ARIA) reported Q2 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $13.65 million.
Net product revenues from sales of Iclusig were $11.9 million for the quarter ended June 30, 2014. Net... More
ARIAD Pharma (ARIA), Medison Enter Agreement for Iclusig in Israel
August 5, 2014 7:36 AM EDTARIAD Pharma (Nasdaq: ARIA) announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.
Under the terms of the agreement, ARIAD Pharmaceuticals (Israel) Ltd will be the Marketing Authorization Holder (MAH) of Iclusig in Israel, and Medison will be responsible for sales and marketing, medical affairs, regulatory support, as well as obtaining, in collaboration with ARIAD, the pricing and reimbursement approval of... More
